Filing Flows › Wave Life Sciences (WVE) › R&D spending
Wave Life Sciences (WVE) R&D spending by quarter
Wave Life Sciences' R&D spending was $53.8M in Q3 2026 (third quarter 2026), +5% from Q2 2026. Over the last 5 quarters it ranged from $40.6M (Q1 2025) to $53.8M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $53.8M | +5% | — |
| Q2 2026 | $51.3M | +8% | +18% |
| Q1 2026 | $47.4M | +9% | +17% |
| Q2 2025 | $43.5M | +7% | — |
| Q1 2025 | $40.6M | — | — |
Q3 2026 at a glance
Wave Life Sciences, Q3 2026: revenue $13.2M (+73% year over year), operating margin -502.0%, net loss $61.9M, operating cash flow −$60.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Wave Life Sciences' R&D spending?
Wave Life Sciences' R&D spending was $53.8M in Q3 2026 (third quarter 2026), +5% from Q2 2026.
How has Wave Life Sciences' R&D spending changed?
Over the last 5 quarters it ranged from $40.6M (Q1 2025) to $53.8M (Q3 2026).